Compare RMT & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RMT | PSNL |
|---|---|---|
| Founded | 1993 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 614.5M | 729.1M |
| IPO Year | N/A | 2019 |
| Metric | RMT | PSNL |
|---|---|---|
| Price | $13.66 | $6.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $12.20 |
| AVG Volume (30 Days) | 130.5K | ★ 1.8M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 7.37% | N/A |
| EPS Growth | N/A | ★ 33.58 |
| EPS | ★ 1.49 | N/A |
| Revenue | N/A | ★ $69,648,000.00 |
| Revenue This Year | N/A | $15.34 |
| Revenue Next Year | N/A | $41.46 |
| P/E Ratio | $9.10 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.27 | $3.84 |
| 52 Week High | $13.64 | $11.50 |
| Indicator | RMT | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 74.12 | 47.69 |
| Support Level | $10.32 | $5.81 |
| Resistance Level | N/A | $6.99 |
| Average True Range (ATR) | 0.24 | 0.46 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 92.68 | 53.00 |
Royce Micro-Cap Trust Inc is a diversified closed-end investment company. The company is engaged in investing in micro-cap securities. It invests in the consumer discretionary sector, including diversified consumer services, hotels, household durables, leisure products, and luxury goods. Consumer staples sector, including beverages, food, and staples retailing, food products, and personal products, Energy sector, including energy equipment and services, and oil, gas, and consumable fuels. The company also invests in other sectors, including healthcare, financials, industrials, IT, telecommunications, and materials.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.